webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Doxorubicin-SMCC

  CAS No.: 400647-59-8   Cat No.: BADC-01122   Purity: >99.3% 4.5  

Doxorubicin-SMCC is a pre-activated ADC linker-payload combining a cytotoxic agent with a maleimide NHS ester linker. Enables targeted drug delivery by conjugating with antibody thiol groups.

Doxorubicin-SMCC

Structure of 400647-59-8

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C39H42N2O14
Molecular Weight
762.76
Shipping
Room temperature
Storage
Store at -5°C,keep in dry and avoid sunlight.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
4-((2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)methyl)-N-((2S,3S,4S,6R)-3-hydroxy-2-methyl-6-(((1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2H-pyran-4-yl)cyclohexanecarboxamide
IUPAC Name
4-[(2,5-dioxopyrrol-1-yl)methyl]-N-[(2S,3S,4S,6R)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]cyclohexane-1-carboxamide
Canonical SMILES
CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)NC(=O)C6CCC(CC6)CN7C(=O)C=CC7=O)O
InChI
InChI=1S/C39H42N2O14/c1-17-33(46)22(40-38(51)19-8-6-18(7-9-19)15-41-26(44)10-11-27(41)45)12-28(54-17)55-24-14-39(52,25(43)16-42)13-21-30(24)37(50)32-31(35(21)48)34(47)20-4-3-5-23(53-2)29(20)36(32)49/h3-5,10-11,17-19,22,24,28,33,42,46,48,50,52H,6-9,12-16H2,1-2H3,(H,40,51)/t17-,18?,19?,22-,24-,28-,33+,39-/m0/s1
InChIKey
OTQOQHVWNBKSGU-SAJDXUNTSA-N
Solubility
10 mm in DMSO
Appearance
Solid powder
Quantity
Milligrams-Grams
Quality Standard
Enterprise standard
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature
Storage
Store at -5°C,keep in dry and avoid sunlight.
Form
Solid

Doxorubicin-SMCC, a pivotal conjugate utilized in targeted cancer therapies and biomedical research, showcases a multitude of applications. Here are four key applications of Doxorubicin-SMCC:

Targeted Cancer Therapy: Pioneering the landscape of targeted cancer therapy, Doxorubicin-SMCC assumes a pivotal role in crafting antibody-drug conjugates (ADCs) tailored to selectively target cancer cells while preserving the integrity of healthy tissues. By conjugating Doxorubicin-SMCC with antibodies recognizing tumor-specific antigens, the drug is precisely delivered to malignant cells, ushering in a paradigm shift in treatment precision and mitigating systemic toxicity, ushering in a sophisticated approach to cancer therapy.

Drug Delivery System Research: Positioned at the forefront of drug delivery system exploration, Doxorubicin-SMCC serves as a cornerstone for delving into and refining drug delivery mechanisms. Researchers delve into the intricate dynamics of stability, release kinetics, and biodistribution of this versatile conjugate across diverse formulations. Revelations derived from unraveling these complexities have the potential to drive the evolution of advanced targeted drug delivery platforms, potentially enhancing treatment outcomes across a spectrum of medical conditions.

Bioconjugation Studies: In the realm of bioconjugation research, Doxorubicin-SMCC emerges as a catalytic agent for dissecting the chemical bonds between drugs and targeting molecules. By harnessing the SMCC linker, researchers securely anchor Doxorubicin to proteins or peptides, paving the way for innovative conjugation strategies. Discoveries stemming from these intricate studies hold the promise of catalyzing the development of novel therapeutics and diagnostic tools.

What is Doxorubicin-SMCC?

Doxorubicin-SMCC is an ADC linker-payload conjugate combining doxorubicin with the SMCC linker. It is designed for controlled intracellular release following antibody-mediated endocytosis, enabling selective cytotoxicity while maintaining conjugate stability in circulation for research and development purposes.

29/8/2020

Could you advise on the recommended storage conditions for Doxorubicin-SMCC?

Doxorubicin-SMCC should be stored at low temperatures under inert atmosphere, protected from light and moisture. Proper storage maintains chemical integrity, prevents premature degradation, and ensures reproducibility of ADC experiments and preclinical evaluations.

12/8/2021

We would like to know what specifications are available for Doxorubicin-SMCC.

Doxorubicin-SMCC is provided with detailed specifications including molecular weight, linker chemistry, and solubility characteristics. These parameters support ADC design, formulation, and experimental reproducibility without disclosing purity values.

10/10/2022

Dear team, are there support documents available for Doxorubicin-SMCC?

Yes, Doxorubicin-SMCC is supplied with comprehensive technical documentation, including chemical structure, handling instructions, and suggested conjugation protocols. These documents aid researchers in optimizing ADC construction and experimental workflows.

19/7/2020

Good morning! How is the quality of Doxorubicin-SMCC typically tested?

Quality of Doxorubicin-SMCC is verified through analytical techniques such as NMR, LC-MS, and HPLC for structural confirmation and stability assessment. This ensures the linker-payload is suitable for ADC research applications.

7/7/2019

— Dr. James Carter, Senior Scientist (USA)

We tested Doxorubicin-SMCC in our ADC development project and were impressed by its exceptional purity and consistency. It streamlined our conjugation workflow significantly.

10/10/2022

— Prof. Anna Müller, Biochemistry Researcher (Germany)

BOC Sciences delivered Doxorubicin-SMCC ahead of schedule, which allowed us to accelerate our preclinical testing. Highly recommended for reliable ADC research.

7/7/2019

— Dr. Michael Thompson, ADC Development Scientist (UK)

The lot-to-lot consistency of Doxorubicin-SMCC exceeded our expectations. It facilitated reproducible results in our cytotoxicity assays.

19/7/2020

— Ms. Emily Johnson, Research Associate (Canada)

Using Doxorubicin-SMCC, we achieved high conjugation efficiency without additional optimization. This product truly enhanced our workflow.

29/8/2020

— Dr. Laurent Dupont, Medicinal Chemist (France)

Doxorubicin-SMCC from BOC Sciences provided excellent solubility and stability, critical for our long-term ADC stability studies.

— Dr. Rachel Smith, Bioconjugation Specialist (USA)

The technical support team provided clear guidance for handling Doxorubicin-SMCC. Their advice helped us achieve optimal yields in ADC synthesis.

12/8/2021

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Bis-PEG17-NHS ester | Bis-PEG25-NHS ester | Bis-PEG6-NHS ester | Bis-PEG21-NHS ester | 2,5-dioxopyrrolidin-1-yl 1-(cyclooct-2-ynyloxy)-2-oxo-6,9,12-trioxa-3-azapentadecan-15-oate | NHS-Ac-N3 | Mal-PEG4-Val-Cit-PAB-OH | Me-Tet-PEG4-NHS | Hydroxy-PEG2-t-butyl ester | succimimidyl-4-azidobutyrate | Doxorubicin-SMCC
Send Inquiry
Verification code
Inquiry Basket